Form 4: United Therapeutics Director Dwek Exercises Options and Sells Shares Under 10b5-1 Plan
SEC Form 4 Filing
Director Raymond Dwek exercised stock options and sold the resulting shares of United Therapeutics Corp (UTHR) on April 7, 2025, under a pre-arranged 10b5-1 trading plan.
Summary
- Raymond Dwek, a director of United Therapeutics Corporation, executed transactions involving the company's common stock on April 7, 2025.
- Dwek exercised stock options to acquire 4,000 shares of common stock at an exercise price of $175.43 per share.
- Simultaneously, Dwek sold 4,000 shares of common stock at a price of $284.55 per share.
- These transactions were conducted under a pre-arranged 10b5-1 trading plan established on August 2, 2024.
- Following these transactions, Dwek directly owns 1,750 shares of United Therapeutics common stock and derivative securities representing 6,000 shares.
Sentiment
Score: 5
Explanation: The sentiment is neutral as it reports routine transactions under a pre-existing plan. There is no indication of positive or negative implications for the company.
Industry Context
This Form 4 filing is a routine disclosure of insider transactions. The use of a 10b5-1 plan suggests that the transactions were pre-planned and not based on any material non-public information.
Key Dates
| Date | Description |
|---|---|
| 08/02/2024 | Date of establishment of the 10b5-1 trading plan |
| 06/26/2016 | Stock Option Date Exercisable |
| 04/07/2025 | Date of stock option exercise and sale of shares |
| 06/26/2025 | Stock Option Expiration Date |
| 04/08/2025 | Date of Form 4 signature |
Keywords
Form 4, United Therapeutics, UTHR, Raymond Dwek, Stock Options, 10b5-1 Plan, Director, Insider Trading
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.